Research Samples
WBB Securities reinitiates coverage on LivaNova plc with a Hold Rating and reduced the target price to $60.00 after seeing a drop in sales of certain LivaNova business lines.
WBB Securities updates coverage of Scynexis, Inc. from a Speculative Buy to a Buy and reiterated an $8.00 price target after the company disclosed encouraging interim data from a Phase II trial of its lead product. Scynexis develops anti-infectives for anti-fungal use.  Its first drug candidate, SCY-078, is a first-in-class IV and oral anti-fungal being tested for treatment of invasive fungal infections caused by Candida and Aspergillus.